They emphasize the therapeutic potential of targeting DDX3, also and perhaps particularly in tumors with DDX3X mutations and upregulation of DDX3Y and suggest that a combination of drugs targeting DDX3 with those that enhance oxidative stress may represent promising therapeutic avenues for human BL. Here, DDX3X is linked to Burkitt lymphoma.